The Biosimilar Revolution: Assessing the European Union's Approach to Biosimilarity, Interchangeability, Patient...

The biosimilar revolution alters the biopharmaceutical environment, delivering an appropriate strategy for improving accessibility and cutting healthcare costs. The European Union (EU) has established a broad regulatory structure to ensure the proper and efficient use of biosimilars. This review examines the EU's approach to biosimilarity, interchangeability, and patient access, encompassing the legal framework, scientific considerations, market dynamics, and patient viewpoints. The EU's regulatory system has developed to accommodate biosimilar development, approval, and adoption difficulties. Biosimilarity involves demonstrating comparability to the reference product, whereas interchangeability necessitates a more nuanced approach. Patient access is affected by pricing, reimbursement, and education. Employing a mixed-methods approach, this review combines an evaluation of regulatory documents, scientific literature, and market survey analysis. This review looks at the accomplishments and obstacles of the EU's strategy, identifying areas for advancement and chances for further development. This review intends to give significant insights to stakeholders, such as policymakers, producers, medical professionals, and patients, by examining the EU's biosimilar revolution. This critique helps to shape initiatives to improve the EU's approach, boost patient access, and promote sustainable healthcare systems. Ultimately, this review demonstrates that the EU's approach to biosimilars has successfully increased market growth and suggested suitable areas for development.